Page 18 - Preclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of Novartis Building on NIBR foundation, Dr. Marshall to shape next era of biomedical innovation and continue Novartis leadership in R&D Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis. Fiona H.

01.09.2022 - After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr. Marshall to shape next era of biomedical innovation ... Seite 1

/PRNewswire/ -- The "Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug Type (Small, Large Molecules), by Therapeutic Area...

Dublin, June 28, 2022 (GLOBE NEWSWIRE) -- The "Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug Type (Small, Large...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.